Loading stock data…
RCUS
$24.86-0.50 (-1.97%)
Market ClosedLast close May 11
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcus Biosciences, Inc. in the Healthcare sector is trading at $24.86. The stock is currently near its 52-week high of $28.72, remaining 30.5% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why RCUS maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.86
Potential Upside
5%
Whystock Fair Value$26.10
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$34.18+37.5%
Range$20.00 – $47.00
Fundamentals
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney ca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.23%
Volume
Today's trading volume
451,894
Recent News
Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter Report
As you might know, Arcus Biosciences, Inc. ( NYSE:RCUS ) last week released its latest quarterly, and things did not...
Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift
Arcus Biosciences (NYSE:RCUS) ended its Phase 3 STAR-121 lung cancer trial after a futility analysis indicated the study was unlikely to meet its goals. Gilead decided not to continue its broad option rights within the collaboration, changing how the two companies work together on future programs. These developments remove a late stage lung cancer program from Arcus's pipeline and reshape the partnership framework with a key pharmaceutical partner. For investors tracking Arcus Biosciences...
Arcus Biosciences, Inc. Q1 2026 Earnings Call Summary
Moby summary of Arcus Biosciences, Inc.'s Q1 2026 earnings call
Arcus (RCUS) Q1 2026 Earnings Call Transcript
Arcus Biosciences, Inc. has proven to be a highly productive company creating and advancing a steady stream of potential best-in-class molecules for patients with cancer and inflammatory and autoimmune diseases. Since its inception, Arcus Biosciences, Inc. has advanced molecules from program initiation to IND filing in as short as 18 months, and through an accelerated platform and signal-seeking study, moved from proof-of-concept Phase 1 studies to randomized Phase 2 and registrational Phase 3 trials in just a few years. Today, the company is laser focused on cascadifan, which represents a market opportunity of more than $5 billion in kidney cancer alone.
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -10.87% and +21.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?